Founder
Kumar Shah, M.D.
Founder, President & Chief Clinical Researcher
Kumar Shah, M.D., is the Founder, President, and Chief Clinical Researcher of Endocrine Technology, LLC and its spin-off biotechnology company ETBONDAI Private Limited. He is a board-certified physician in Internal Medicine, Diabetes, Endocrinology, and Metabolism, and is the 100% owner and principal inventor behind the company’s intellectual property portfolio. With more than 30 years of experience in both life sciences and the biotechnology industry, Dr. Shah has built a dual-competency foundation that spans clinical medicine, immunology, endocrine research, and translational biotechnology.
Dr. Shah’s career began as an executive in the Clinical Research Division of Roche Products, Mumbai (1973–1974), where he directed early pharmaceutical research programs. After relocating to the United States, he joined Montefiore Hospital, Bronx, NY (1978–1981) as a Clinical Research Fellow in the Steroid Research Division, collaborating with oncologists on chemotherapy protocols. During this time, he also came in contact with Dr. Rosalyn Yalow, Nobel laureate for radioimmunoassay, who allowed him to take basic training in radioimmunoassay and provided guidance for future research. His subsequent training included an Endocrinology fellowship at the VA Hospital, East Orange, NJ, and an Internal Medicine residency at Brooklyn Hospital.
Since 1984, Dr. Shah has served as a Senior Attending Physician at Brooklyn Hospital and has maintained a consulting practice in Internal Medicine and Endocrinology. His clinical practice has supported the infrastructure, laboratory operations, and patent development of Endocrine Technology since its formation.
Dr. Shah operated a New York State–compliant Radioimmunoassay Laboratory (1986–2004) under CLIA regulations, providing diagnostic endocrine testing and supporting translational research. He also served as a volunteer consultant in the establishment of the Cell Transplant Laboratory at the Institute of Kidney Diseases, Ahmedabad, under the leadership of Dr. H. L. Trivedi (1994–1996).
Dr. Shah’s work centers on controlled modulation of the complement system, specifically Factor H and Factor D, and the development of polysulfone-based immune modulation technologies. His inventions span encapsulated cell devices, islet transplantation machinery, and polymer-based immune therapies.
Professional appointments
- Director, Clinical Research, Roche Products (Hoffman-La Roche), Mumbai — 1973–1974
- Bergen Pines Hospital, Paramus, NJ — 1974
- Neptune Hospital, Neptune, NJ — 1975
- Montefiore Hospital, Bronx, NY, Clinical Research Fellowship — 1978–1981
- Brooklyn Hospital, Medical Residency — 1982
- VA Hospital, East Orange, NJ, Endocrine Fellowship — 1983
- Senior Attending Physician, Brooklyn Hospital — 1984–Present
- Consulting Physician, Internal Medicine — 1984–Present
- Voluntary Consultant, Cell Transplant Laboratory, Ahmedabad — 1994–1996
- President, Endocrine Technology, LLC — 2002–Present
- Director, Radioimmunoassay Laboratory (NY State & CLIA) — 1986–2004
Memberships
- American Medical Association
- New York Medical Association
Publications
- Application of Recent Advances in Immunology to Develop Novel Biotechnology Products in India, book chapter, 2008 (edited by Langer, Bioplan Associates)
- Controlled Modulation of Factor H and Factor D, abstract, Complement Conference (CH 2009), September 1–3, 2009
Patents
- U.S. Patent 6,805,857 (2004) — modulating Factor D, Factor H, and CD4 cell immune response
- U.S. Patent 5,976,780 (1999) — Encapsulated Cell Device
- U.S. Patent 5,837,444 — Islet Cell Transplantation Machine
- India patent — Method for Encapsulated Polymers, 2011
Research support
- Federal grant: $1.22 million (2010), Qualified Drug Discovery Projects
- New York State biotechnology grants: $1–2 million (2010)
- Keynote, “Reengineering Diabetes,” July 20–21, Paris
- Ongoing support from Endocrine Technology, ETBOND research, and private consulting practice since 1984